吸入糖皮质激素下调慢阻肺患者SARS-CoV-2相关基因表达:一项随机对照试验结果
一项纳入63例慢阻肺患者的随机对照试验显示,与单用LABA相比,ICS/LABA治疗12周可下调支气管上皮细胞中SARS-CoV-2相关基因ACE2和ADAM17的表达。这可能对慢阻肺患者COVID-19易感性和严重程度产生影响。
要点
- ICS/LABA治疗12周可下调慢阻肺患者支气管上皮ACE2和ADAM17表达。
- 该作用可能影响慢阻肺患者对COVID-19的易感性和结局。
- 观察性研究已显示慢阻肺与COVID-19严重程度和死亡率增加相关。
核心结论
- 在慢阻肺患者中,ICS/LABA治疗12周较单用LABA下调支气管上皮细胞SARS-CoV-2相关基因ACE2和ADAM17的表达。
研究设计与样本
- 随机对照试验,纳入63例慢阻肺患者,比较ICS/LABA与单用LABA治疗12周对支气管上皮细胞SARS-CoV-2相关基因表达的影响。
主要发现
- 与单用LABA相比,ICS/LABA治疗12周下调支气管上皮细胞ACE2和ADAM17的表达。
临床怎么用
- 慢阻肺患者使用ICS/LABA可能通过下调ACE2和ADAM17影响COVID-19易感性和严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In a RCT of 63 patients with COPD, 12 weeks of ICS/LABA therapy downregulated bronchial epithelial expression of the SARS-CoV-2-related genes ACE2 and ADAM17 compared to LABA alone. This may have implications for COVID-19 susceptibility/severity in COPD. https://bit.ly/3vZnBVO Observational studies show that COPD is associated with increased coronavirus disease 2019 (COVID-19) severity and mortality [1]. Inhaled corticosteroids (ICS), which are commonly used to treat COPD, have been associated with increased risk of bacterial pneumonia in COPD and impaired immune response to viruses. Whether this class of medication affects the airway expression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptors and cofactors (changes which may modify COVID-19 susceptibility and outcomes) is currently unclear. Therefore, we examined the effects of ICS treatment on SARS-CoV-2-related gene expression in lower airway bronchial epithelial cells (BECs) in a randomised controlled trial of COPD patients.
引用
- Milne S, Li X, Yang CX, et al. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial. Eur Respir J. 2021. PMID: 33795322. doi:10.1183/13993003.00130-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。